New Delhi [India], February 2 (ANI): Dr Krishna Ella, Chairman and Managing Director of Bharat Biotech on Wednesday welcomed the Union Budget 2022 and said that during COVID-19 pandemic budget outlay in the healthcare sector and vaccine self-reliance has helped the biotech industry.

Chandigarh Jan 24 PTI Bharat Biotech International Limited Chairman Dr Krishna Ella on Monday said todays neglected infectious diseases could be tomorrows global pandemic and stressed the need to have a coherent strategy to fight them He said this during an event organised as part of the 38 foundation day celebrations by CSIR-Institute of Microbial Technology IMTECH Chandigarh Bharat Biotechs Covaxin is credited to be Indias first indigenous COVID-19 vaccine to be approved and administered to a sizeable population across the globe Delivering this years foundation day lecture virtually on Innovation and Leadership in Pandemic Ella highlighted how todays neglected infectious diseases could be tomorrows global pandemic and stressed the need to have a coherent strategy to fight infectious diseases according to an CSIR-IMTECH statement During his lecture Dr Ella highlighted how innovative technology in vaccine development is essential to solve public healthcare problems caused by infectious diseases He said Indian pharmaceutical companies need to innovate beyond generic vaccines to be a global player in the vaccine market He stressed the need for scientists to examine the unknowns that could be the future cause of pandemic through zoonotic and unknown viruses A serial entrepreneur with a passion for innovative ideas Bharat Biotech has also ventured into veterinary vaccines food processing and developing biotechnology infrastructure in the country Dr Ella is also involved in shaping Indias science education and policy through his association with several committees said the statement Dr Shekhar C Mande Secretary Department of Scientific and Industrial Research Director General CSIR asked scientists to focus on microbiome therapies which could be future game changer for treating diseases Dr Sanjeev Khosla Director CSIR-IMTECH lauded efforts of scientists and researchers for the work carried out to fight the pandemic during the challenging times of COVID-19 The CSIR-IMTECH is a national centre for excellence in microbial sciences and was established in 1984 PTI SUN RDK RDK

Washington [US], December 29 (ANI): Former MLB star Alex Rodriguez, who has been in the headlines after his split from fiance-singer Jennifer Lopez, has again grabbed eyeballs for praising his ex-wife Cynthia Scurtis in a special note on her birthday.

Washington [US], November 27 (ANI): Alex Rodriguez seems to be highly grateful on this year's Thanksgiving as he celebrated the special occasion with his ex-wife Cynthia Scurti and their two daughters--- Natasha and Ella.

New Delhi [India], November 11 (ANI): People will need booster doses of the COVID-19 vaccine would be required if the COVID-19 virus gets mutated, said Chairman and Managing Director of Bharat Biotech, Dr Krishna Ella.

New Delhi [India], October 23(ANI): Chairman and Managing Director of Bharat Biotech, Dr. Krishna Ella on Saturday said that they are waiting for approval from the Drugs Controller General of India (DCGI) for the COVID-19 vaccine for children.

Hyderabad Sept 21 PTI Bharat Biotech has completed the Phase 23 trials of COVID-19 vaccine Covaxin for use in children under 18 years of age and is expected to submit the data by next week to the DCGI Chairman and Managing Director of Bharat Biotech International Ltd Krishna Ella said on Tuesday here Speaking to reporters he said Covaxin production would touch 55 million doses in October as against 35 million in September He also said the Phase 2 trials of the firms intranasal vaccine against COVID-19 is expected to be over by next month Paediatric Covaxin just completed phase 23 trials The data analysis is going on We will be submitting the data to the regulator by next week The number of subjects volunteers is touching 1000 Ella said Intranasal immunization can create an immune response in the nose which is the point of entry for the virusthereby protecting against the disease infection and transmission also he noted According to Ella the intranasal vaccine trials are conducted on three cohorts in which one group is administered Covaxin as the first dose and intranasal as the second Similarly intranasal-intranasal for the second group and Intranasal- Covaxin for the third cohort 28 days apart He said the trials will be conducted on about 650 volunteers On the production levels of Covaxin Ella said 100 million doses per month can be possible if the other manufacturing partners are fully geared up with safety and other parameters are in place Other than its own facilities Bharat Biotech has tied up with Indian Immunologiclas and Hester Biosciences to manufacture Covaxin We are supplying 35 million this month Next month we will be definitely supplying 55 million doses Production at Bangalore is catching up very fast he said replying to a query On exports of Covaxin to other countries Ella said if the Centre permits the firm is ready to export the jab though the firm is not in a hurry to look for overseas markets According to him the governments focus is to fulfill domestic requirements India will resume export of surplus Covid-19 vaccines in the fourth quarter of 2021 under the Vaccine Maitri programme and to meet its commitment to the COVAX global pool but vaccinating its own citizens remains the topmost priority of the government Union Health Minister Mansukh Mandaviya said on Monday PTI GDK ROH ROH